英菲格拉替尼的用法用量是怎样的？有什么副作用？

Infigratinib is an oral FGFR selective inhibitor. On May 28, 2021, the US FDA accelerated approval of infigratinib for adult patients with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. It can prolong the patient's progression-free survival, have a positive effect on the patient's condition, and improve the patient's quality of life and disease progression.

What is the dosage of Infigratinib?

The recommended dosage of infigratinib will vary depending on the severity of the disease, but it is necessary to determine whether there is FGFR2 gene fusion or rearrangement before using this product. Infigratinib needs to be taken on an empty stomach, at least one hour before meals or 2 hours after meals. The recommended dose is 125 mg, taken orally once a day, with a treatment cycle of 28 days, with 21 consecutive days of medication and 7 days of drug withdrawal. Infigratinib cannot be crushed, chewed, or dissolved; the capsule must be swallowed whole. For patients with mild and moderate renal impairment: the recommended dose is 100 mg; for patients with mild hepatic impairment: the recommended dose is 100 mg; for patients with moderate hepatic impairment: the recommended dose is 75 mg.

What are the side effects of Infigratinib?

Although Infigratinib has significant therapeutic effects, it also has side effects. Nail toxicity, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, stomatitis, dry eye syndrome, fatigue, hair loss, palmoplantar erythema syndrome, joint pain, diarrhea, dry skin, loss of appetite, blurred vision and vomiting are common side effects of Infigratinib. Patients have different constitutions, different conditions, and different side effects. It is recommended that patients follow the doctor's advice and receive symptomatic treatment.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: